Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma
Thymic stromal lymphopoietin (TSLP) is an innate cytokine, belonging to the group of alarmins, which plays a key pathogenic role in asthma by acting as an upstream activator of cellular and molecular pathways leading to type 2 (T2-high) airway inflammation. Released from airway epithelial cells upon...
Main Authors: | Corrado Pelaia, Giulia Pelaia, Claudia Crimi, Angelantonio Maglio, Luca Gallelli, Rosa Terracciano, Alessandro Vatrella |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-04-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/9/4369 |
Similar Items
-
Monoclonal Antibodies Targeting Alarmins: A New Perspective for Biological Therapies of Severe Asthma
by: Corrado Pelaia, et al.
Published: (2021-08-01) -
Novel Biological Therapies for Severe Asthma Endotypes
by: Corrado Pelaia, et al.
Published: (2022-05-01) -
TSLP and HMGB1: Inflammatory Targets and Potential Biomarkers for Precision Medicine in Asthma and COPD
by: Fabiana Furci, et al.
Published: (2023-02-01) -
A case of type 2 diabetes mellitus with weight gain and worsening of glycemic management after tezepelumab administration for severe bronchial asthma
by: Kotaro Umamoto, et al.
Published: (2024-03-01) -
Specific Therapy for T2 Asthma
by: Diego Bagnasco, et al.
Published: (2022-04-01)